Data / Drug companies / GlaxoSmithKline LLC
GlaxoSmithKline LLC: 77 products in the FDA NDC directory, labeler code 0173
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
GlaxoSmithKline LLC (labeler code 0173) lists 77 products in the FDA National Drug Code Directory, covering 25 finished drugs by generic name. By type: 77 prescription drugs. Its main marketing category is new drug applications (NDA). The newest product started marketing on October 20, 2026.
The request: Watch GlaxoSmithKline LLC (FDA labeler code 0173): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 0173
- Products in commercial distribution
- 77
- Packages
- 107
- Finished drugs by generic name
- 25
- Prescription products
- 77
- Over the counter products
- 0
- Flagged as original packager
- 70 of 70 products that carry the flag
- Started marketing in the last 12 months
- 3
- Products with a marketing end date set
- 5
- Earliest marketing start
- January 17, 1995
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 71 | 92.2% |
| Biologics (BLA) | 6 | 7.8% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 77 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Lamotrigine | 25 | 51 |
| Sumatriptan | 6 | 28 |
| Daprodustat | 5 | 1 |
| Fluticasone furoate | 3 | 4 |
| Fluticasone furoate and vilanterol trifenatate | 3 | 1 |
| Mepolizumab | 3 | 1 |
| Fluticasone propionate and salmeterol xinafoate | 3 | 3 |
| Fluticasone propionate and salmeterol | 3 | 14 |
| Bupropion hydrochloride | 3 | 67 |
| Niraparib | 3 | 1 |
| Atovaquone | 2 | 19 |
| Atovaquone and proguanil hydrochloride | 2 | 9 |
| Valacyclovir hydrochloride | 2 | 28 |
| Salmeterol xinafoate | 1 | 1 |
| Albuterol sulfate | 1 | 46 |
| Zanamivir | 1 | 2 |
| Tebipenem pivoxil | 1 | 1 |
| Umeclidinium bromide and vilanterol trifenatate | 1 | 2 |
| Belantamab mafodotin | 1 | 1 |
| Gepotidacin | 1 | 1 |
| Dostarlimab | 1 | 1 |
| Umeclidinium | 1 | 2 |
| Depemokimab | 1 | 1 |
| Bepirovirsen | 1 | 1 |
| Tafenoquine succinate | 1 | 1 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 21 | 27.3% |
| Powder | 13 | 16.9% |
| Kit | 8 | 10.4% |
| Tablet, film coated, extended release | 6 | 7.8% |
| Injection | 4 | 5.2% |
| Aerosol, metered | 4 | 5.2% |
| Injection, solution | 4 | 5.2% |
| Tablet, orally disintegrating | 4 | 5.2% |
| Tablet | 4 | 5.2% |
| Tablet, for suspension | 3 | 3.9% |
| Suspension | 2 | 2.6% |
| Injection, powder, for solution | 2 | 2.6% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Anti-epileptic Agent | 17 |
| Mood Stabilizer | 17 |
| Corticosteroid | 14 |
| beta2-Adrenergic Agonist | 14 |
| Serotonin-1b and Serotonin-1d Receptor Agonist | 6 |
| Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor | 5 |
| Anticholinergic | 4 |
| Antimalarial | 4 |
| Antiprotozoal | 4 |
| Interleukin-5 Antagonist | 3 |
| Aminoketone | 3 |
| Poly(ADP-Ribose) Polymerase Inhibitor | 3 |
| Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor | 2 |
| Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor | 2 |
| Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor | 2 |
| Neuraminidase Inhibitor | 1 |
| Triazaacenaphthylene Bacterial Type II Topoisomerase Inhibitor | 1 |
| Programmed Death Receptor-1 Blocking Antibody | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Hibsago | 0173-0941 | Injection, solution | New drug applications (NDA) | October 20, 2026 |
| Utebzi | 0173-0956 | Tablet, film coated | New drug applications (NDA) | October 1, 2026 |
| Exdensur | 0173-0927 | Injection, solution | Biologics (BLA) | December 16, 2025 |
| Blenrep | 0173-0913 | Injection, powder, for solution | Biologics (BLA) | October 23, 2025 |
| Blujepa | 0173-0922 | Tablet, film coated | New drug applications (NDA) | March 25, 2025 |
| Zejula | 0173-0915 | Tablet, film coated | New drug applications (NDA) | June 27, 2023 |
| Zejula | 0173-0912 | Tablet, film coated | New drug applications (NDA) | June 27, 2023 |
| Zejula | 0173-0909 | Tablet, film coated | New drug applications (NDA) | June 27, 2023 |
| Breo Ellipta | 0173-0916 | Powder | New drug applications (NDA) | May 12, 2023 |
| Jesduvroq | 0173-0914 | Tablet, film coated | New drug applications (NDA) | February 1, 2023 |
| Jesduvroq | 0173-0911 | Tablet, film coated | New drug applications (NDA) | February 1, 2023 |
| Jesduvroq | 0173-0906 | Tablet, film coated | New drug applications (NDA) | February 1, 2023 |
| Jesduvroq | 0173-0903 | Tablet, film coated | New drug applications (NDA) | February 1, 2023 |
| Jesduvroq | 0173-0897 | Tablet, film coated | New drug applications (NDA) | February 1, 2023 |
| Nucala | 0173-0904 | Injection, solution | Biologics (BLA) | January 22, 2022 |
| Jemperli | 0173-0898 | Injection | Biologics (BLA) | April 22, 2021 |
| Trelegy Ellipta | 0173-0893 | Powder | New drug applications (NDA) | September 9, 2020 |
| Nucala | 0173-0892 | Injection, solution | Biologics (BLA) | June 6, 2019 |
| Krintafel | 0173-0889 | Tablet, film coated | New drug applications (NDA) | January 22, 2019 |
| Arnuity Ellipta | 0173-0888 | Powder | New drug applications (NDA) | May 17, 2018 |
| Trelegy Ellipta | 0173-0887 | Powder | New drug applications (NDA) | September 18, 2017 |
| Nucala | 0173-0881 | Injection, powder, for solution | Biologics (BLA) | November 4, 2015 |
| Breo Ellipta | 0173-0882 | Powder | New drug applications (NDA) | April 30, 2015 |
| Arnuity Ellipta | 0173-0876 | Powder | New drug applications (NDA) | August 20, 2014 |
| Arnuity Ellipta | 0173-0874 | Powder | New drug applications (NDA) | August 20, 2014 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.